Navigation Links
Interim Report for the Period 1 January - 30 September 2008 (Unaudited)
Date:11/26/2008

VEDBAEK, Denmark, November 26 /PRNewswire-FirstCall/ -- Exiqon A/S, traded at the NASDAQ OMX Copenhagen ("EXQ"), reports continued strong growth in research product sales during the third quarter of 2008. Revenues were positively affected by the execution of a license agreement with Roche Diagnostics for use of Exiqon's LNA(TM) technology. Initial fourth quarter sales were negatively affected by supply of arrays that failed Exiqon's internal quality tests causing a slow down in executed sales orders. Although the supply problems have now been addressed, Exiqon revises its 2008 total year guidance of revenue of DKK 140-150 million to now DKK 120-130 million. As a result, a net loss of DKK 115-125 is now anticipated compared to previous expectations of a net loss of DKK 100-115 million.

    - Revenue in the third quarter of 2008 increased five fold on the
      year-earlier period to DKK 51.3 million, totaling DKK 95.8 million in
      the first nine months of 2008.

    - Compared third quarter last year product sales increased by 329% to DKK
      28 million totaling DKK 68,5 million in the first nine months of 2008.
      Research product sales grew organically by 141%.

    - Net loss for the third quarter of 2008 was DKK 10.1 million totaling
      DKK 73.6 million in the first nine months of 2008. EPS amounted to DKK
      -0.35 in the third quarter of 2008 and DKK -2.55 in the first nine
      months of 2008.

    - License granted to Roche Diagnostics for use of Exiqon's proprietary
      LNA(TM) detection technology in a new product line for RealTime ready
      qPCR assays demonstrates the value of LNA(TM) as a detection
      technology.

    - The integration of former Oncotech Inc - now Exiqon Diagnostics Inc -
      remains on track for the first miRNA diagnostic product launch to be
      announced in December 2008.

Lars Kongsbak, President and CEO says: "Product demand remains stron
'/>"/>

SOURCE Exiqon A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
2. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
3. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
4. Misonix Announces Interim Distribution Agreement for Italy
5. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
6. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
7. Arpida Reports Interim Results for Six Months to 30 June 2008
8. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
9. LPBP Inc. - Re-filing certification of interim filings
10. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
11. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... BRAINTREE, Mass. , May 20, 2015  Haemonetics ... Brian Concannon , President & CEO, will present at ... New York on June 1 st , ... public may access Mr. Concannon,s presentation live via webcast ... Haemonetics Haemonetics (NYSE: HAE ) is a ...
(Date:5/20/2015)... SEATTLE , May 20, 2015  Resolution Bioscience ... of ctDx ALK TM , a blood-based liquid ... non-small cell lung carcinoma (NSCLC), the most common form ... the test to guide patients to personalized therapies and ... sample. The Department of Health, the CLIA ...
(Date:5/20/2015)... North Carolina , 20. Mai ... Unternehmen für klinische Logistik (Clinical Logistics ... das Geschäftsjahr 2014, das am 31. ... Das Unternehmen hat die Marktentwicklung übertroffen ... Logo - http://photos.prnewswire.com/prnh/20110930/NY78064LOGO ...
(Date:5/20/2015)... The Greater Gift Initiative, Inc ., (GGI) ... announce they are donating 10,010 vaccines today in recognition ... effort and commitment of clinical trial volunteers who participated ... 2014. , With a mission to advance global ... participation, GGI supports International Clinical Trials Day and how ...
Breaking Biology Technology:Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2Marken schließt Ergebnisse für das Geschäftsjahr 2014 ab 2The Greater Gift Initiative Donates over 10,000 Vaccines in Honor of International Clinical Trials Day 2
... , NOVATO, Calif., June 10 BioMarin Pharmaceutical Inc. (Nasdaq: ... notice of priority review status for Kuvan(R) (sapropterin dihydrochloride) as ... Canada. Priority review provides for a shortened submission review ... plans to file a marketing application for Kuvan in Canada ...
... , MINNEAPOLIS, June 10 Charles A. Dinarello, M.D., a ... Medicine in Denver and a member of the Techne Corporation ... , , On April 26, 2009, Dr. Dinarello, ... Bruce Beutler, M.D., of The Scripps Research Institute , ...
... June 10 It doesn,t take long after,you,ve polished ... are,forcefully reminded of it in the restroom. Some people ... after urinating. The unmistakable olfactory,experience is caused by organic ... of our Podcast listeners on,Chemistry in our everyday life. ...
Cached Biology Technology:Kuvan Receives Priority Review Status From Health Canada 2Kuvan Receives Priority Review Status From Health Canada 3Kuvan Receives Priority Review Status From Health Canada 4Techne Corporation Board Member Recognized 2BASF Podcast: The Chemical Reporter - Why Does Your Urine Smell so Different After You've Eaten Asparagus? 2BASF Podcast: The Chemical Reporter - Why Does Your Urine Smell so Different After You've Eaten Asparagus? 3
(Date:4/27/2015)... Conn. , Apr. 27, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... commence shipping to pre-order customers the first week of ... through the month of May. ... a significant milestone for the company as Wocket® enters ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... 26, 2013 MedNet Solutions , a global ... systems, is pleased to announce that Accelovance , ... early phase Oncology, Vaccines and General Medicine development, has ... Program .    Designation as an iMedNet Partner ...
... citrus greening, looms darkly over the United States, threatening ... fruit alone was valued at more than $3.4 billion ... by a University of California, Davis, plant scientist used ... how citrus greening impacts trees before they even show ...
... than $25 million over four years will help three ... of genomic variants relevant to human disease and the ... practice. The awards are from the National Institutes of ... sequencing the DNA of whole genomes (the body,s entire ...
Cached Biology News:MedNet Solutions Proudly Welcomes Accelovance To The iMedNet Partner Program 2MedNet Solutions Proudly Welcomes Accelovance To The iMedNet Partner Program 3New study offers hope for halting incurable citrus disease 2New study offers hope for halting incurable citrus disease 3New NIH-funded resource focuses on use of genomic variants in medical care 2New NIH-funded resource focuses on use of genomic variants in medical care 3
Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
Ultra-sensitive, non-radioactive detection of rat Big Endothelin-1 (Big ET-1)...
Qa-1 (L-12)...
Request Info...
Biology Products: